125 related articles for article (PubMed ID: 24778042)
21. A randomized, phase 2 trial of Docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic non-small-cell lung cancer.
Levy B; Spira A; Becker D; Evans T; Schnadig I; Camidge DR; Bauman JE; Hausman D; Walker L; Nemunaitis J; Rudin CM; Halmos B; Bowles DW
J Thorac Oncol; 2014 Jul; 9(7):1031-1035. PubMed ID: 24926548
[TBL] [Abstract][Full Text] [Related]
22. Panitumumab, Gemcitabine, and Carboplatin as Treatment for Women With Metastatic Triple-Negative Breast Cancer: A Sarah Cannon Research Institute Phase II Trial.
Yardley DA; Ward PJ; Daniel BR; Eakle JF; Lamar RE; Lane CM; Hainsworth JD
Clin Breast Cancer; 2016 Oct; 16(5):349-355. PubMed ID: 27340049
[TBL] [Abstract][Full Text] [Related]
23. Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma.
Burotto M; Edgerly M; Poruchynsky M; Velarde M; Wilkerson J; Kotz H; Bates S; Balasubramaniam S; Fojo T
Oncologist; 2015 Jul; 20(7):725-6. PubMed ID: 26040622
[TBL] [Abstract][Full Text] [Related]
24. Everolimus-containing therapy vs conventional therapy in the treatment of refractory breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study.
Chen Z; Zheng Y; Cao W; Zhang Y; Zhao Z; Wang G; Zhao J; Cai S; Shao X; Huang J; Ye W; Huang Y; Li W; Huang X; Wu H; Wang X; Yin Y
Cancer Med; 2019 Sep; 8(12):5544-5553. PubMed ID: 31385461
[TBL] [Abstract][Full Text] [Related]
25. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens.
Ng K; Tabernero J; Hwang J; Bajetta E; Sharma S; Del Prete SA; Arrowsmith ER; Ryan DP; Sedova M; Jin J; Malek K; Fuchs CS
Clin Cancer Res; 2013 Jul; 19(14):3987-95. PubMed ID: 23743569
[TBL] [Abstract][Full Text] [Related]
26. Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix.
Wright AA; Howitt BE; Myers AP; Dahlberg SE; Palescandolo E; Van Hummelen P; MacConaill LE; Shoni M; Wagle N; Jones RT; Quick CM; Laury A; Katz IT; Hahn WC; Matulonis UA; Hirsch MS
Cancer; 2013 Nov; 119(21):3776-83. PubMed ID: 24037752
[TBL] [Abstract][Full Text] [Related]
27. The Impact of Systemic Therapy Beyond First-line Treatment for Advanced Cervical Cancer.
McLachlan J; Boussios S; Okines A; Glaessgen D; Bodlar S; Kalaitzaki R; Taylor A; Lalondrelle S; Gore M; Kaye S; Banerjee S
Clin Oncol (R Coll Radiol); 2017 Mar; 29(3):153-160. PubMed ID: 27838135
[TBL] [Abstract][Full Text] [Related]
28. Liquid biopsy of PIK3CA mutations in cervical cancer in Hong Kong Chinese women.
Chung TKH; Cheung TH; Yim SF; Yu MY; Chiu RWK; Lo KWK; Lee IPC; Wong RRY; Lau KKM; Wang VW; Worley MJ; Elias KM; Fiascone SJ; Smith DI; Berkowitz RS; Wong YF
Gynecol Oncol; 2017 Aug; 146(2):334-339. PubMed ID: 28587748
[TBL] [Abstract][Full Text] [Related]
29. Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.
Lachkar B; Minaguchi T; Akiyama A; Liu S; Zhang S; Xu C; Shikama A; Tasaka N; Sakurai M; Nakao S; Ochi H; Yoshikawa H; Satoh T
Medicine (Baltimore); 2018 Aug; 97(31):e11392. PubMed ID: 30075505
[TBL] [Abstract][Full Text] [Related]
30. Phase 2 study of TAS-117, an allosteric akt inhibitor in advanced solid tumors harboring phosphatidylinositol 3-kinase/v-akt murine thymoma viral oncogene homolog gene mutations.
Lee JB; Jung M; Beom SH; Kim GM; Kim HR; Choi HJ; Sohn JH; Ahn JB; Rha SY; Chung HC
Invest New Drugs; 2021 Oct; 39(5):1366-1374. PubMed ID: 33723724
[TBL] [Abstract][Full Text] [Related]
31. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial.
Oaknin A; Friedman CF; Roman LD; D'Souza A; Brana I; Bidard FC; Goldman J; Alvarez EA; Boni V; ElNaggar AC; Passalacqua R; Do KTM; Santin AD; Keyvanjah K; Xu F; Eli LD; Lalani AS; Bryce RP; Hyman DM; Meric-Bernstam F; Solit DB; Monk BJ
Gynecol Oncol; 2020 Oct; 159(1):150-156. PubMed ID: 32723675
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
[TBL] [Abstract][Full Text] [Related]
33. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
34. Clinical and genetic landscape of treatment naive cervical cancer: Alterations in PIK3CA and in epigenetic modulators associated with sub-optimal outcome.
Scholl S; Popovic M; de la Rochefordiere A; Girard E; Dureau S; Mandic A; Koprivsek K; Samet N; Craina M; Margan M; Samuels S; Zijlmans H; Kenter G; Hillemanns P; Dema S; Dema A; Malenkovic G; Djuran B; Floquet A; Garbay D; Guyon F; Colombo PE; Fabbro M; Kerr C; Ngo C; Lecuru F; Campo ERD; Coutant C; Marchal F; Mesgouez-Nebout N; Fourchotte V; Feron JG; Morice P; Deutsch E; Wimberger P; Classe JM; Gleeson N; von der Leyen H; Minsat M; Dubot C; Gestraud P; Kereszt A; Nagy I; Balint B; Berns E; Jordanova E; Saint-Jorre N; Savignoni A; Servant N; Hupe P; de Koning L; Fumoleau P; Rouzier R; Kamal M
EBioMedicine; 2019 May; 43():253-260. PubMed ID: 30952619
[TBL] [Abstract][Full Text] [Related]
35. Prognostic Value of BRAF, PI3K, PTEN, EGFR Copy Number, Amphiregulin and Epiregulin Status in Patients with KRAS Codon 12 Wild-Type Metastatic Colorectal Cancer Receiving First-Line Chemotherapy with Anti-EGFR Therapy.
Llovet P; Sastre J; Ortega JS; Bando I; Ferrer M; García-Alfonso P; Donnay O; Carrato A; Jiménez A; Aranda E; León A; Grávalos C; Cámara JC; Feliú J; Sanchíz B; Caldés T; Díaz-Rubio E
Mol Diagn Ther; 2015 Dec; 19(6):397-408. PubMed ID: 26341080
[TBL] [Abstract][Full Text] [Related]
36. PIK3CA Mutations and Their Impact on Survival Outcomes of Patients with Cervical Cancer: A Systematic Review.
Pergialiotis V; Nikolaou C; Haidopoulos D; Frountzas M; Thomakos N; Bellos I; Papapanagiotou A; Rodolakis A
Acta Cytol; 2020; 64(6):547-555. PubMed ID: 32683364
[TBL] [Abstract][Full Text] [Related]
37. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
38. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F; Hurvitz S; Fasolo A; Tseng LM; Jerusalem G; Wilks S; O'Regan R; Isaacs C; Toi M; Burris H; He W; Robinson D; Riester M; Taran T; Chen D; Slamon D
J Clin Oncol; 2016 Jun; 34(18):2115-24. PubMed ID: 27091708
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients.
Beelen K; Opdam M; Severson TM; Koornstra RH; Vincent AD; Wesseling J; Muris JJ; Berns EM; Vermorken JB; van Diest PJ; Linn SC
Breast Cancer Res; 2014 Jan; 16(1):R13. PubMed ID: 24467828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
